Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human, randomized, placebo-controlled, double-blind, sequential single and multiple ascending dose (SAD/MAD) study with open-label food effect and pharmacodynamic assessment arms to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-3024

Next Previous
Trial Profile

A first-in-human, randomized, placebo-controlled, double-blind, sequential single and multiple ascending dose (SAD/MAD) study with open-label food effect and pharmacodynamic assessment arms to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-3024

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACI 3024 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man
  • Sponsors AC Immune

Most Recent Events

  • 23 Mar 2021 Status changed from recruiting to completed, according to an AC Immune media release.
  • 30 Mar 2020 According to an AC Immune media release, results are expected in Q2 2020 and data disclosure by partner is expected in H2 2020.
  • 20 Sep 2019 According to an AC Immune media release, company will receive the first milestone payment of CHF30 million from Eli Lilly and Company on or before October 7, 2019 follows initiation of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top